Cancer: Phosphodiesterase type 4C (PDE4C), the forgotten subfamily as a therapeutic target

Int J Biochem Cell Biol. 2023 Jul 25;162:106453. doi: 10.1016/j.biocel.2023.106453. Online ahead of print.ABSTRACTPhosphodiesterase type 4 (PDE4) enzymes specifically hydrolyse cAMP in many cell signalling systems that are transduced by hormones and other primary messengers. The physiological function of the four PDE4 subfamilies (A, B, C and D) are numerous and varied due to the differentially localised plethora of isoforms that can be detected in cardiovascular, CNS and immune systems. Of the four subfamilies, least is known about PDE4C probably due to its restricted distribution pattern, scarcity of selective inhibitors and the lack of developed research tools. Here, for the first time, we chart the discovery of PDE4C, describe its regulation and highlight cancers where future development of PDE4C selective small molecules may have potential.PMID:37499270 | DOI:10.1016/j.biocel.2023.106453
Source: The International Journal of Biochemistry and Cell Biology - Category: Biochemistry Authors: Source Type: research